Genzyme and Isis provide update on CHMP opinion on KYNAMRO™ (mipomersen)
14 December 2012 | By Sanofi
"We are disappointed by the Committee's recommendation..."
List view / Grid view
14 December 2012 | By Sanofi
"We are disappointed by the Committee's recommendation..."
9 December 2012 | By Sanofi
New data presented at American Society of Hematology Annual Meeting show activity against disease and symptom alleviation...
3 December 2012 | By Sanofi
American Society of Hematology, Atlanta, GA., 8-11 December, 2012...
28 November 2012 | By Sanofi
Sanofi ranked third among twenty pharmaceutical companies on the 2012 Access to Medicine Index (ATM Index)...
16 November 2012 | By Sanofi
“We are pleased that CHMP has supported our ZALTRAP application..."
16 November 2012 | By Sanofi
“The CHMP positive opinion for Lyxumia marks an important milestone..."
14 November 2012 | By Sanofi
Sanofi is pleased to announce the appointment of Dr. Gary J. Nabel...
14 November 2012 | By
Collaboratation on the TEENs registry study...
31 October 2012 | By
Significant effects of LEMTRADA™ vs. Rebif ® described in CARE-MS I and CARE-MS II publications...
18 October 2012 | By Sanofi
"We are very encouraged by the support for KYNAMRO..."
12 October 2012 | By Sanofi
Sanofi and Genzyme announced that key data from the TOWER trial were presented at the 28th Congress of the ECTRIMS...
9 October 2012 | By Sanofi
Sanofi announced the launch by Sanofi India Limited of AllStar™...
9 October 2012 | By Genzyme
New data from Genzyme’s clinical development programs...
Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).
5 October 2012 | By Sanofi
New data from ORIGIN shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population...